MRI of testicular malignancies

Tsili, Athina C.; Sofikitis, Nikolaos; Stiliara, Efrosyni; Argyropoulou, Maria I.

doi:10.1007/s00261-018-1816-5

Cited by 35 publications

(53 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 We used the following terms to search the eligible GEO datasets: ("Germ Cell Tumors" or "Testicular Germ Cell Tumor") and ("outcome" or "prognosis") and ("male"). The eligible studies met the following inclusion criteria: (Tsili et al, 2019) reported research on patients with TCGT; (Zhang et al, 2018) provided sufficient clinical data to calculate overall survival (OS), DFS, or progression-free survival; and (Diamantopoulos and Kortsaris, 2010) provided gene expression profiles of TGCT. Only peer-reviewed studies were deemed eligible for inclusion.…”

Section: External Validations Of the Six-gene Risk Score Using The Gementioning

confidence: 99%

See 1 more Smart Citation

RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor

Yao

Cong

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Testicular germ cell tumors (TGCTs) are common urological neoplasms in young adult males. The outcome of TGCT depends on pathologic type and tumor stage. RNA-binding proteins (RBPs) influence numerous cancers via post-transcriptional regulation. The prognostic importance of RBPs in TGCT has not been fully investigated. In this study, we set up a prognostic risk model of TGCT using six significantly differentially expressed RBPs, namely, TRMT61A, POLR2J, DIS3L2, IFIH1, IGHMBP2, and NPM2. The expression profiles were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. We observed by performing least absolute shrinkage and selection operator (LASSO) regression analyses that in the training cohort, the expression of six RBPs was correlated with disease-free survival in patients with TGCT. We assessed the specificity and sensitivity of 1-, 3-, 5-, and 10-year survival status prediction using receiver operating characteristic curve analysis and successfully validated using the test cohorts, the entire TCGA cohort, and Gene Expression Omnibus (GEO) datasets. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analyses were carried out to seek the possible signaling pathways related with risk score. We also examined the association between the model based on six RBPs and different clinical characteristics. A nomogram was established for TGCT recurrence prediction. Consensus clustering analysis was carried out to identify the clusters of TGCT with different clinical outcomes. Ultimately, external validations of the six-gene risk score were performed by using the GSE3218 and GSE10783 datasets downloaded from the GEO database. In general, our study constructed a prognostic model based on six RBPs, which could serve as independent risk factor in TGCT, especially in seminoma, and might have brilliant clinical application value.

show abstract

Section: External Validations Of the Six-gene Risk Score Using The Gementioning

confidence: 99%

“…Testicular germ cell tumors (TGCTs) are the most common malignant neoplasms in young adult males between 20 and 40 years old despite being regarded as rare tumor types that account for only 1% of solid neoplasms in men (Tsili et al, 2019). TGCT has two main subtypes: seminoma and non-seminoma.…”

Section: Introductionmentioning

confidence: 99%

RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor

Yao

Cong

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Radical orchiectomy is the main treatment for testicular tumors and can be supplemented by radiotherapy and chemotherapy (4, 5). In view of the different sensitivities of seminomas and nonseminomas to radiotherapy and chemotherapy, characterizing the histologic type of testicular tumors is of great importance (6–8). For patients undergoing orchidectomy, the differentiation of seminomas from nonseminomas would not affect patient management.…”

Section: Introductionmentioning

confidence: 99%

“…T2-weighted imaging (T2WI) is an essential component of MRI in oncology. Some previous studies reported that seminomas and nonseminomas have different features on T2WI (8, 9). Most of the previous studies only used qualitative features or limited quantitative features, which may not fully explore the potential value of MRI.…”

Section: Introductionmentioning

confidence: 99%

T2-Weighted Image-Based Radiomics Signature for Discriminating Between Seminomas and Nonseminoma

et al. 2019

View full text Add to dashboard Cite

Objective: To evaluate the performance of a T2-weighted image (T2WI)-based radiomics signature for differentiating between seminomas and nonseminomas.Materials and Methods: In this retrospective study, 39 patients with testicular germ-cell tumors (TGCTs) confirmed by radical orchiectomy were enrolled, including 19 cases of seminomas and 20 cases of nonseminomas. All patients underwent 3T magnetic resonance imaging (MRI) before radical orchiectomy. Eight hundred fifty-one radiomics features were extracted from the T2WI of each patient. Intra- and interclass correlation coefficients were used to select the features with excellent stability and repeatability. Then, we used the minimum-redundancy maximum-relevance (mRMR) and the least absolute shrinkage and selection operator (LASSO) algorithms for feature selection and radiomics signature development. Receiver operating characteristic curve analysis was used to evaluate the diagnostic performance of the radiomics signature.Results: Five features were selected to build the radiomics signature. The radiomics signature was significantly different between the seminomas and nonseminomas (p < 0.01). The area under the curve (AUC), sensitivity, and specificity of the radiomics signature for discriminating between seminomas and nonseminomas were 0.979 (95% CI: 0.873–1.000), 90.00 (95% CI: 68.3–98.8), and 100.00 (95% CI: 82.4–100.0), respectively.Conclusion: The T2WI-based radiomics signature has the potential to non-invasively discriminate between seminomas and nonseminomas.

show abstract

“…Native B-mode ultrasound has been regarded as the primary imaging modality for the evaluation of testicular lesions for a long time [4]. However, more recently the use of color-coded Doppler sonography (CCDS) and especially of more advanced imaging techniques like contrast-enhanced ultrasound (CEUS) has been advocated as CEUS, for example, can more accurately differentiate between benign and malignant testicular lesions especially in small non-palpable intratesticular lesions (< 1.5 cm of size) as it shows a higher diagnostic accuracy, thus reducing the need for repeated expensive procedures such as MRI [1,[5][6][7][8][9]. Native B-mode ultrasound has been seen as an unsatisfactory imaging method for differentiating benign from malignant intratesticular lesions lately and it has been claimed that CEUS can significantly increase diagnostic accuracy [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Should We Use Contrast-Enhanced Ultrasound (CEUS) for the Characterization of Nonpalpable Testicular Lesions? An Analysis from a Cost-Effectiveness Perspective

et al. 2019

View full text Add to dashboard Cite

Purpose Accurate characterization of testicular lesions is crucial to allow for correct treatment of malignant tumors and to avoid unnecessary procedures in benign ones. In recent years, contrast-enhanced ultrasound (CEUS) proved to be superior in specifying the dignity of small, nonpalpable testicular lesions (< 1.5 cm) compared to native B-mode and color Doppler ultrasound which were previously regarded as the primary imaging method. However, the cost-effectiveness of CEUS has not been evaluated yet. The aim of this study was to analyze the cost-effectiveness of CEUS as compared to unenhanced ultrasound for the characterization of nonpalpable testicular lesions. Methods A decision model based on Markov simulations estimated lifetime costs and quality-adjusted life years (QALYs) associated with unenhanced ultrasound and CEUS. Model input parameters were obtained from recent literature. Deterministic sensitivity analysis of diagnostic parameters and costs was performed. Also, probabilistic sensitivity analysis using Monte-Carlo Modelling was applied. The willingness-to-pay (WTP) was set to $100 000/QALY. Results In the base-case scenario, unenhanced ultrasound resulted in total costs of $5113.14 and an expected effectiveness of 8.29 QALYs, whereas CEUS resulted in total costs of $4397.77 with 8.35 QALYs. Therefore, the unenhanced ultrasound strategy was dominated by CEUS in the base-case scenario. Sensitivity analysis showed CEUS to be the cost-effective alternative along a broad range of costs. Conclusion Contrast-enhanced ultrasound is a cost-effective imaging method for the characterization of nonpalpable testicular lesions.

show abstract

MRI of testicular malignancies

Cited by 35 publications

References 48 publications

RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor

RNA-Binding Proteins Play an Important Role in the Prognosis of Patients With Testicular Germ Cell Tumor

T2-Weighted Image-Based Radiomics Signature for Discriminating Between Seminomas and Nonseminoma

Should We Use Contrast-Enhanced Ultrasound (CEUS) for the Characterization of Nonpalpable Testicular Lesions? An Analysis from a Cost-Effectiveness Perspective

Contact Info

Product

Resources

About